Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | SCD | O00767 | 5/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385665 | 0.91 | SCD (0.41) | EPHX2CYP2C9CYP2J2SCDSCD5 | |
| SCHEMBL69306 | 0.91 | SCD (0.41) | EPHX2CYP2C9CYP2J2SCDSCD5 | |
| SCHEMBL29385670 | 0.90 | EPHX2 (0.47) | EPHX2SCDSCD5P2RY12MAPT | |
| SCHEMBL69558 | 0.90 | EPHX2 (0.47) | EPHX2SCDSCD5P2RY12MAPT | |
| SCHEMBL70186 | 0.90 | SCD (0.42) | EPHX2SCDSCD5HRH1CCR3 | |
| SCHEMBL70613 | 0.87 | SCD (0.42) | SCDP2RY12 | |
| SCHEMBL29382083 | 0.87 | EPHX2 (0.49) | EPHX2CNR1SCDSCD5 | |
| SCHEMBL70064 | 0.87 | EPHX2 (0.47) | EPHX2CNR1SCDSCD5HRH1 | |
| SCHEMBL68443 | 0.87 | EPHX2 (0.49) | EPHX2CNR1SCDSCD5 | |
| SCHEMBL70664 | 0.87 | SCD (0.46) | EPHX2CYP2C9CYP2J2SCDSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | claimed |
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | EPHX2 1185/4885CYP2C9 3233/4885CYP2J2 3226/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | EPHX2 1023/4885CYP2C9 2849/4885CYP2J2 761/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | EPHX2 1185/4885CYP2C9 3233/4885CYP2J2 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.